Researcher comment: SELECT-PsA-1 | Frank Behrens

preview_player
Показать описание
Frank Behrens discusses the findings from a phase 3 trial comparing upadacitinib with placebo and adalimumab in patients with psoriatic arthritis and an inadequate response to non-biologic DMARDs

Рекомендации по теме